Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2026-07-05 @ 10:50 PM
Study NCT ID:
NCT02094235
Status:
COMPLETED
Last Update Posted:
2025-06-04
First Post:
2014-03-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis
Sponsor:
Organon and Co
Organization:
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter, double-blind, vehicle-control study of 0.05% and 0.2% E6005 ointment. Pediatric subjects with atopic dermatitis (AD) will be grouped into two; an elder group (childhood - adolescent: 7 to 15 years of age) and a younger group (children: 2 to 6 years of age) according to the sequential cohorts by confirming the safety.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: